Cellebrite Di Stock Earnings Reports

Key points for investors:

- Strong Q1 financials: ARR grew 21% YoY to $493M; revenue $128.3M (up 19%); adjusted EBITDA $30.6M (up 29%); trailing-12-month free cash flow margin ~32%; cash, cash equivalents & investments ~$535M. Headcount 1,271. Corellium costs absorbed for the quarter; SCG acquisition closed.

- Q2 outlook and full-year posture: Q2 ARR guidance $510M–$513M (net new ARR $17M–$20M), revenue guidance $130M–$133M, adjusted EBITDA $29M–$31M. Company confirms full-year guide and expects product-driven acceleration in H2. FX is a modest headwind.

- AI product momentum: Genesis (agentic investigative AI) publicly announced March 16, pre-GA trials produced >500 registered early users across 15+ countries with strong, unsolicited customer praise. Management expects GA mid‑June and that AI revenue—previously modeled as zero for 2026—will contribute meaningfully going forward. Management estimates an Investigative AI TAM of ~$12.5B over four years and sees AI as a potential path to materially expand ARR (management says it could approach doubling the business with strong execution).

- Product & platform milestones: Guardian Investigate (AI-powered evidence/case management) moved to general availability; advanced Android/iOS unlock capabilities improved in late Q1; on‑prem AI options in development. FedRAMP High ATO achieved (opens U.S. federal opportunities). Drone forensics (SCG) and Corellium strengthen platform breadth.

- Commercial traction and pipeline: U.S. Federal pipeline up ~35% YoY; EMEA ARR growth accelerated to ~25% with defense & intelligence up mid-30s; management highlights larger, more strategic deals and improving federal momentum. Sales leaders report strong access to investigative users and significant product interest from detective communities.

- Go-to-market & adoption notes: Early Genesis distribution was free for trials to accelerate word-of-mouth; management expects rapid adoption due to demonstrable productivity and life/safety impact. Pricing strategy will be initially aggressive to drive broad adoption; monetization expected post-GA.

- Organizational & risk items: Chief Product & Technology Officer to retire July 1; Shiv Ramji named President of Products and Technology. Management reiterates forward-looking risks and that AI dynamics remain fast-moving and inherently uncertain.